Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AITIK-TKI Discontinuation in CML
2024-515479-36-00Phase 3Authorised
- Sponsor
- CHU de Poitiers
- Start
- Aug 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of imatinib, dasatinib, nilotinib and bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: Treatment-free remission at 24 months. Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-515479-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515479-36-00.